Detalle Publicación

Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on use of trabectedin

Autores: Lorusso, D.; González Martín, Antonio; Ray Coquard, I. (Autor de correspondencia)
Título de la revista: FUTURE ONCOLOGY
ISSN: 1479-6694
Volumen: 17
Número: 3S
Páginas: 9 - 19
Fecha de publicación: 2021
Following failure of first-line platinum-based chemotherapy in ovarian cancer, options for further therapy in potentially platinum-responsive patients are: carboplatin doublets with pegylated liposomal doxorubicin, gemcitabine or paclitaxel in association with bevacizumab, followed by maintenance with bevacizumab (for nonpretreated patients); or maintenance monotherapy with a poly(ADP-ribose) polymerase inhibitor after a response. The choice of biological therapy depends on a patient's previous treatments and priority for a symptomatic response. In cases of a rapidly growing tumor or need for symptomatic relief, the addition of bevacizumab should be considered. Patients with limited potential sensitivity to platinum, such as those with a platinum treatment-free interval of 6-12 months, may benefit from intercalation with trabectedin and pegylated liposomal doxorubicin to possibly restore platinum sensitivity.